Evidence map›Paper›PMID 37471169›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2024

Nanomedicines for Improved Management of Ectopic Pregnancy: A Narrative Review.

Abraham S Moses, Tetiana Korzun, Babak Mamnoon, Maureen K Baldwin, Leslie Myatt, Oleh Taratula, Olena R Taratula

Open access · greenAbstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Abraham S MosesDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.
Tetiana KorzunDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.
Babak MamnoonDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.
Maureen K BaldwinDepartment of Obstetrics and Gynecology, School of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Leslie MyattDepartment of Obstetrics and Gynecology, School of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Oleh TaratulaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.
Olena R TaratulaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.ORCID 0000-0001-8657-036X
Oregon State University · USOregon Health & Science University · US

Funding

OHSU Women's Reproductive Health Research K12 ProgramK12HD085809 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Aaron B Caughey · 2015 to 2026
$4.0M
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic HyperthermiaR01CA237569 · NCI · OREGON STATE UNIVERSITY · PI TARATULA, OLEH · 2020 to 2024
$2.7M
Nanocarriers for placenta-specific delivery of imaging and therapeutic agentsR03TR004020 · NCATS · OREGON STATE UNIVERSITY · PI TARATULA, OLENA · 2022 to 2023
$141k
College of Pharmacy at Oregon State University, National Center for Advancing Translational Sciences of National Institutes of Health NIH/NCATSCollege of Pharmacy at Oregon State University, National Center for Advancing Translational Sciences of National Institutes of Health R03 TR004020-01National Cancer Institute of the National Institutes of Health R01CA237569NCATS NIH HHS R03 TR004020NCI NIH HHS R01 CA237569
6 · The paper itself

Abstract

Ectopic pregnancy (EP) - the implantation of an embryo outside of the endometrial cavity, often in the fallopian tube - is a significant contributor to maternal morbidity and leading cause of maternal death due to hemorrhage in first trimester. Current diagnostic modalities including human chorionic gonadotropin (hCG) quantification and ultrasonography are effective, but may still misdiagnose EP at initial examination in many cases. Depending on the patient's hemodynamic stability and gestational duration of the pregnancy, as assessed by history, hCG measurement and ultrasonography, management strategies may include expectant management, chemotherapeutic treatment using methotrexate (MTX), or surgical intervention. While these strategies are largely successful, expectant management may result in tubal rupture if the pregnancy does not resolve spontaneously; MTX administration is not always successful and may induce significant side effects; and surgical intervention may result in loss of the already-damaged fallopian tube, further hampering the patient's subsequent attempts to conceive. Nanomaterial-based technologies offer the potential to enhance delivery of diagnostic imaging contrast and therapeutic agents to more effectively and safely manage EP. The purpose of this narrative review is to summarize the current state of nanomedicine technology dedicated to its potential to improve both the diagnosis and treatment of EP.

Indexed as

NanomedicinePregnancy, EctopicFemaleHumansMethotrexatePregnancyMethotrexatealternative treatmentsectopic pregnancynanomedicineplacenta imaging

Identifiers

PMID37471169
PMCPMC10837845
OpenAlexW4384922325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.